AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS PERSPECTIVE OF THE ANIMAL ...
AB Science says a newly identified blood biomarker may help assess masitinib activity in its ongoing Phase 3 ALS clinical trial.
PRESS RELEASEAB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC ...
Ab Science ((ABSCF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
AB Science SA (Euronext - FR0010557264 - AB) today announced that the confirmatory Phase 3 study with masitinib in amyotrophic lateral sclerosis (ALS), study AB23005, has been authorized by the first ...
Good morning, and good afternoon for the participant to our web conference organized by AB Science. About an update of the clinical development of our asset called AB8939. My name is Alain Moussy, I'm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results